Kwangdong Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kwangdong Pharmaceutical makes medicines and health-care products supplied to consumers and patients in South Korea.
The company is listed on KOSPI, South Korea's main stock exchange, and operates across both prescription pharmaceuticals and consumer health products. Because the filing text provided does not detail specific product lines or structural facts, the business is best described at the general level of a diversified Korean pharmaceutical company.
Summary is AI-generated and may contain errors · figures from DART filings
Kwangdong Pharmaceutical in five facts
What does Kwangdong Pharmaceutical do?
Kwangdong Pharmaceutical makes medicines and health-care products supplied to consumers and patients in South Korea.
Where is Kwangdong Pharmaceutical listed and in which sector?
Kwangdong Pharmaceutical (Korean name: 광동제약) trades under KRX code 009290 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kwangdong Pharmaceutical?
Its market capitalisation was US$251.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kwangdong Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Kwangdong Pharmaceutical reported revenue of US$1.3B, operating profit of US$23.4M and net income of US$16.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 1.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 12
- Report on large shareholdings (5% rule) (standard)Oct 2
- Operating results (consolidated) (preliminary) (fair disclosure)
Kwangdong Pharmaceutical filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$311M (+3.4% year on year), operating profit of US$1.99M (−37.8% year on year) and net income of US$2.23M (+32.1% year on year).
Earnings · Aug 12 - Material event report (treasury share disposal)
Kwangdong Pharmaceutical disclosed a plan to sell treasury shares worth US$684K, about 0.3% of its market value.
Treasury Shares · Mar 26 - Cash/in-kind dividend decision
Kwangdong Pharmaceutical declared a cash dividend of US$0.07 per share.
Dividend · Feb 23 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kwangdong Pharmaceutical reported consolidated results for FY2025: revenue of US$1.14B (+1.1% year on year), operating profit of US$21.3M (+3.2% year on year) and net income of US$16.1M (−43.9% year on year).
Earnings · Feb 10